Claus Werenberg Marcher

Claus Werenberg Marcher

Auto-generated profile, based on publicly available information

Claus Werenberg Marcher

Department of Hematology, Odense University Hospital, Odense, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
LØLene Sofie Granfeldt Østgård
Lene Sofie Granfeldt Østgård
JLJennifer L. Lund
Jennifer L. Lund
JNJan Maxwell Nørgaard
Jan Maxwell Nørgaard
MNMette Nørgaard
Mette Nørgaard
BMBruno C. Medeiros
Bruno C. Medeiros
HSHenrik Sengeløv
Henrik Sengeløv
To examine the outcomes of allogeneic stem cell transplantation (HSCT) in first complete remission (CR1) compared with chemotherapy alone in a population-based setting, we identified a cohort of patients with acute myeloid leukemia (AML) aged 15 to 70 years diagnosed between 2000 and 2014 in Denmark. Using the Danish National Acute Leukemia Registry, we compared relapse risk, relapse-free survival (RFS), and overall survival (OS) between patients with unfavorable cytogenetic features receiving postremission therapy with conventional chemotherapy only versus those undergoing HSCT in CR1. To minimize immortal time bias, we performed Cox proportional hazards regression, included date of allogeneic HSCT as a time-dependent covariate, and stratified the results by age (<60 or ≥60 years) and cytogenetic risk group. Overall, 1031 patients achieved a CR1. Of these, 196 patients (19%) underwent HSCT. HSCT was associated with a lower relapse rate (24% versus 49%) despite a similar median time to relapse (287 days versus 265 days). In all subgroups, the risk of relapse was lower and both RFS and OS were superior in recipients of HSCT (OS, adjusted mortality ratios: all patients, .54 [95% confidence interval (CI), .42-.71]; patients age <60 years, .58 [95% CI, .42-.81]; patients age ≥60 years, .42 [95% CI, .26-.69]; patients with intermediate-risk cytogenetics, .63 [95% CI, .43-.87]; patients with adverse-risk cytogenetics, .40 [95% CI, .24-.67]). In conclusion, in this population-based nationwide cohort study, HSCT was associated with improved survival in both younger and older patients and in patients with both intermediate and adverse cytogenetic risk.

25 July 2023 in European Journal of Haematology
Verified
Journal Article
Open access
DKDaniel Tuyet Kristensen
Daniel Tuyet Kristensen
RBRasmus Froberg Brøndum
Rasmus Froberg Brøndum
AØAndreas Due Ørskov
Andreas Due Ørskov
CMClaus Werenberg Marcher
Claus Werenberg Marcher
CSClaudia Schöllkopf
Claudia Schöllkopf
ARAnne Stidsholt Roug
Anne Stidsholt Roug
Background: The treatment of relapsed or refractory (R/R) acute myeloid leukaemia (AML) remains challenging and outcomes extremely poor. The introduction of venetoclax has transformed the treatment of AML and emerging data suggest that venetoclax‐based therapy may enforce salvage treatment.Materials and Methods: In this nationwide Danish retrospective study, we analysed treatment outcomes of venetoclax‐based salvage treatment for R/R AML between 2019 and 2022. Only venetoclax‐naive patients who had previously received treatment with intensive chemotherapy therapy were included.Results: The cohort consisted of 43 R/R patients with a median age of 57 years. Nine (20.9%) were primary refractory and 34 (79.1%) patients had relapsed, including 21 after previous allogeneic stem cell transplantation. The overall response rate was 76.2% including 61.9% with composite complete remission (CRc: CR + CRi). Among CRc‐responders with information on measurable residual disease (MRD), 8/13 (61.5%) obtained an MRD‐negativity response. The overall survival was 9.3 months for all patients with an estimated 1‐year overall survival of 34%. For CRc‐responders the median overall survival was 13.3 months, and the median relapse‐free survival was 12.8 months.Conclusion: Venetoclax‐based salvage treatment for R/R AML produced high response rates; however, for most patients the response was of limited duration. This study is limited by an observational design and prone to selection bias.

12 March 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
TNTherese Maria Henriette Naur
Therese Maria Henriette Naur
LJLasse Hjort Jakobsen
Lasse Hjort Jakobsen
ARAnne Stidsholt Roug
Anne Stidsholt Roug
TETarec Christoffer El-Galaly
Tarec Christoffer El-Galaly
CMClaus Werenberg Marcher
Claus Werenberg Marcher
MSMarianne Tang Severinsen
Marianne Tang Severinsen
In a recent study by our group we showed a disappointing absence of survival improvement among elderly acute myeloid leukemia (AML) patients from 2001 until 2016. The importance of which is undersc...

21 July 2025 in British Journal of Haematology
Verified
Journal Article
Open access
RJRikke Hedegaard Jensen
Rikke Hedegaard Jensen
CTChristian Teglgaard
Christian Teglgaard
Jonas Faartoft JensenJonas Faartoft Jensen
Jonas Faartoft Jensen
JBJoachim Baech
Joachim Baech
CMClaus Werenberg Marcher
Claus Werenberg Marcher
MSMarianne Tang Severinsen
Marianne Tang Severinsen
Summary: Anthracycline‐containing chemotherapy is associated with cardiovascular diseases (CVDs). While knowledge regarding the extent of cardiotoxicity in adult patients with acute myeloid leukaemia (AML) is sparse, anthracyclines remain a key component in the treatment. To address this, 1379 adult AML patients treated with anthracycline‐containing chemotherapy between 2000 and 2020 were matched to 6895 comparators from the Danish background population and followed for a median of 11.8 and 12.8 years respectively. The risk of congestive heart failure (CHF) was higher in AML patients compared to the comparators throughout the entire follow‐up period with adjusted hazard ratios (HRs) ranging from 15.0 (95% CI: 7.02–32.1) after 3 months to 2.68 (95% CI: 1.67–4.30) after 15 years. The risk of non‐CHF CVD was initially higher in AML patients (adjusted HR: 9.16 [95% CI: 6.61–12.7] after 3 months) but converged to that of the comparators after approximately 10 years. Among AML patients, increasing age and male sex were identified as risk factors of CHF and non‐CHF CVD. In summary, AML patients treated with anthracycline‐containing chemotherapy had an elevated risk of CVD, particularly during the first years after treatment initiation. Increased focus on early detection and cardioprotective strategies may help mitigate the harmful effects of anthracyclines in the future.

28 August 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
DKDaniel Tuyet Kristensen
Daniel Tuyet Kristensen
RBRasmus Froberg Brøndum
Rasmus Froberg Brøndum
MKMichael Knudsen
Michael Knudsen
MSMarianne Tang Severinsen
Marianne Tang Severinsen
LGLykke Grubach
Lykke Grubach
ARAnne Stidsholt Roug
Anne Stidsholt Roug

12 November 2019 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
STStinne Tranekær
Stinne Tranekær
CMClaus Werenberg Marcher
Claus Werenberg Marcher
HHenrik Frederiksen
Henrik Frederiksen
DHDennis Lund Hansen
Dennis Lund Hansen